Yet another inspection by the Food and Drug Administration underscores the difficulties that Pfizer (PFE) is having with a key plant that has been responsible for severe shortages of injectables and other drugs.

The problems at the McPherson, Kan., facility, which Pfizer inherited as part of its $16 billion acquisition of Hospira three years ago, include employees who lack training to manufacture, process, or package products; a failure to review unexplained discrepancies in batches of medicines; and inadequate procedures to prevent contamination, according to an agency inspection report last July and August and posted on the FDA web site on Thursday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy